Diseases of the Kidney & Urinary Tract, Phase II-III

Treating Kidney Disease in Patients with APOL1

Volunteers
Health Professionals

What is the purpose of this trial?

If you are 18-65 years old, diagnosed with kidney disease, and not diabetic, you may be eligible for a clinical trial that is testing an investigational medication to treat APOL1-Mediated Kidney Disease (AMKD). AMKD is caused by genetic variations, which occur commonly in people with African ancestry, and can increase your risk of reaching end-stage kidney disease. Interested participants will receive investigational genetic testing to see if they carry the disease-causing APOL1 genes. Qualified participants will be compensated for study-related time and reimbursement for travel.

Trial with
Vertex Pharmaceuticals, Inc.
Ages
18 years - 60 years
Gender
Both

Find out more about who can participate in this trial

Contact Information

For more information about this study, including how to volunteer, contact Lawrence Ullman Jr.

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

Create a volunteer profile

Principal Investigator

Jeffrey Turner, MD
Associate Professor Term; Co-Director Yale Hypertension Clinic, Nephrology; Nephrology Elective Director, Nephrology; Medical Director Davita Branford, Nephrology, Yale School of Medicine

Sub-Investigator

Randy Luciano, MD, PhD

Last Updated
07/01/2024
Study HIC
#2000030942